Skip to main content

Cachexia (Wasting Syndrome) and cannabis in Georgia

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
Up to 20 fluid ounces o…
POSSESSION
$25/yr
STATE FEE
1–14 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Georgia statute and program

The Georgia Low-THC Oil Patient Registry is the operating authority for Georgia patient certification. The authoritative legal text is: O.C.G.A. § 16-12-200 et seq.: Low-THC Oil / Hope Act. The program portal is at Georgia Low-THC Oil Patient Registry.

What the evidence says about cannabis and Cachexia (Wasting Syndrome)

Cachexia is a complex metabolic syndrome characterized by severe involuntary weight loss, muscle wasting, anorexia (loss of appetite), and weakness in the setting of chronic illness. Most commonly cancer, HIV/AIDS, end-stage organ failure, and severe chronic obstructive pulmonary disease. It is distinct from simple starvation: nutritional support alone often fails to reverse the underlying metabolic dysregulation.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Cachexia (Wasting Syndrome) page.

How to qualify in Georgia

The Georgia Low-THC Oil Patient Registry requires the following registration steps for a Cachexia (Wasting Syndrome) patient (or any qualifying diagnosis):

  1. Get a written physician certification under Haleigh’s Hope Act. A Georgia-licensed physician must certify the patient for one of the enumerated qualifying conditions under O.C.G.A. §31-2A-18 (cancer, ALS, seizure disorders, MS, Crohn’s, Parkinson’s, mitochondrial disease, sickle-cell disease, Tourette’s, autism, severe epidermolysis bullosa, peripheral neuropathy, terminal illness, severe or end-stage AIDS, Alzheimer’s, PTSD, intractable pain, and hospice-eligible patients). The physician submits the certification electronically to the Georgia Department of Public Health.
  2. Complete the Low-THC Oil Patient Registry application. After the physician submits the certification, the patient visits the closest Georgia Department of Public Health (DPH) office or a county health department to complete the registration in person. The patient brings a Georgia driver license or state ID and the $25 application fee.
  3. Pay the $25 state fee and receive the Low-THC Oil Registry card. The biennial Low-THC Oil Registry Card fee is $25, paid by check or money order at the time of in-person registration. Caregivers are added for an additional $25 and must pass a state background check. The card is issued the same day in most cases.
  4. Purchase low-THC oil from a Georgia Access to Medical Cannabis Commission dispensary. Georgia operates a low-THC-oil-only program (oil with no more than 5% THC). With the Low-THC Oil Registry card, patients may possess up to 20 fluid ounces of low-THC oil and purchase from the limited number of Georgia Access to Medical Cannabis Commission (GMCC) licensed dispensaries that launched in 2023. The program does not authorize flower, edibles, or vapor products and does not honor out-of-state medical cards.
State registration fee
$25
Physician visit (typical)
$125–$250
Certification to card
1–14 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Georgia registration steps, fees, and reciprocity rules, see the Georgia cannabis-laws page.

ICD-10 code

A certifying physician documenting Cachexia (Wasting Syndrome) for the Georgia medical cannabis program will typically record ICD-10 R64 or SNOMED-CT 238108007 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Georgia list Cachexia (Wasting Syndrome) as a qualifying condition for medical cannabis?

No. Georgia's qualifying-condition list does not currently include Cachexia (Wasting Syndrome), and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Cachexia (Wasting Syndrome) in Georgia have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Georgia program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a Georgia medical marijuana card for Cachexia (Wasting Syndrome)?

Because Georgia does not currently list Cachexia (Wasting Syndrome) as a qualifying condition, a card for Cachexia (Wasting Syndrome) alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Georgia who is registered with Georgia Low-THC Oil Patient Registry and willing to evaluate Cachexia (Wasting Syndrome) cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Georgia does not honor out-of-state cards, so the certification process has to originate inside the state. The state minimum patient age is 18; minors generally require a parent or legal guardian to act as caregiver. The authoritative source for the current process is the Georgia Low-THC Oil Patient Registry site at https://gmcc.georgia.gov/; the state updates fees, forms, and physician registration rules periodically.

What does the evidence say about cannabis for Cachexia (Wasting Syndrome)?

For Cachexia (Wasting Syndrome), evidence is described as moderate (supportive controlled studies exist but the picture is mixed). The mmjnow condition page for Cachexia (Wasting Syndrome) lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Cachexia (Wasting Syndrome) should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Cachexia (Wasting Syndrome) and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Cachexia (Wasting Syndrome); the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. O.C.G.A. § 16-12-200 et seq.: Low-THC Oil / Hope Actaccessed May 15, 2026
  2. Georgia Access to Medical Cannabis Commissionaccessed May 15, 2026
  3. NORML: Georgia Laws & Penaltiesaccessed May 15, 2026
  4. O.C.G.A. §16-13-2: Possession of marijuana (less than 1 oz)accessed May 17, 2026
  5. O.C.G.A. §16-13-30: Sale, possession with intent, manufacture; penalty scheduleaccessed May 17, 2026
  6. Georgia General Assembly bill trackeraccessed May 17, 2026
  7. City of Atlanta — Cannabis Civil-Fine Ordinance (2017)accessed May 17, 2026
  8. City of Savannah — Cannabis Civil-Fine Ordinance (2018)accessed May 17, 2026
  9. Athens-Clarke County — Civil-Citation Program (2022)accessed May 17, 2026
  10. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 15, 2026
  11. FDA: Dronabinol (Marinol) prescribing informationaccessed May 15, 2026